In this file
‘Safe’ cannot be established for every Zealthy patient with one company-level answer. The relevant assessment involves the person receiving care, their medical history, and the exact medication a clinician proposes.
This file starts with the pharmacy and product information available for Zealthy, then explains what remains for the prescriber and patient to resolve. It is educational research and does not replace an individual clinical assessment.
Identify what would actually be prescribed
References to semaglutide do not identify whether the offered product is a manufacturer-labeled medicine or a compound. Ask for the complete name, formulation, dispensing pharmacy, and indication relevant to the proposed prescription.
Ask for the complete product name, active ingredients, route, concentration, and dispensing pharmacy. A branded approved tablet, an injection, a buccal lozenge, and a compounded sublingual product should not be treated as interchangeable simply because marketing uses the same ingredient name.
Understand the evidence boundary
FDA does not approve compounded drugs or review each preparation for safety, effectiveness, and quality before it is marketed. Compounding can serve a medical need in appropriate circumstances, but a provider should explain why the proposed preparation is needed for the particular patient.
Results from a trial of an approved medicine concern the product and population studied. They do not guarantee an individual result or establish identical performance for another concentration, ingredient combination, route, or pharmacy preparation.
Check the care arrangement
Zealthy markets weight-management care with insurance and self-pay pathways. The relevant questions are whether the care service and the selected drug are covered, and what the membership costs while a coverage decision is outstanding.
Ask Zealthy which professional is responsible for the assessment and how their license can be checked for the patient’s location. Clarify how follow-up happens, how a medication concern reaches the clinician, and when a local examination or another service is needed.
Make room for your health history
Give the clinician a complete list of prescriptions, over-the-counter products, supplements, allergies, relevant conditions, and past treatment reactions. Include medicines obtained from other online services. These details can change which treatment, if any, is appropriate.
Ask about expected side effects, warning symptoms, and practical use of the actual dispensed product. If instructions are unclear, have the prescriber or pharmacist explain them before using it. Do not derive a syringe amount from a different patient’s vial or a social-media dosing chart.
Know how to ask for help
The published telephone number for Zealthy is (877) 870-0323.
Administrative staff can help route a request, but a question about clinical suitability or a medication reaction should reach the treating professional.
The side-effect and contact guide distinguishes routine questions from symptoms requiring prompt or emergency care.
Do not let payment decide the prescription
Its subscription policy describes automatic renewal even if the service is not being used. To stop future billing, follow the account’s membership process and retain confirmation. Ignoring messages is not evidence that a subscription was cancelled.
A prepaid term or promotional offer is not a reason to continue a medicine without discussing a concern. Review the Zealthy cost and commitment details separately from the clinician’s treatment recommendation.
Source notes
Provider material describes the company’s own offer. Official medical references explain clinical and regulatory context; they do not endorse this publication or its commercial partner.
- Online Weight Loss Treatment | Zealthy ↗Provider-published information · Checked September 22, 2026
- Subscription & Cancellation Policy | Zealthy ↗Provider-published information · Checked September 22, 2026
- Terms of Use | Zealthy ↗Provider-published information · Checked September 22, 2026
- Contact Zealthy | Customer Support ↗Provider-published information · Checked September 22, 2026
- FDA: concerns with unapproved GLP-1 drugs ↗Regulatory / public agency · Checked September 22, 2026
- FDA: risks of compounded drugs ↗Regulatory / public agency · Checked September 22, 2026
- FDA: compounded semaglutide dosing errors ↗Regulatory / public agency · Checked September 22, 2026
- MedlinePlus: semaglutide injection ↗Medical reference · Checked September 22, 2026
- MedlinePlus: tirzepatide injection ↗Medical reference · Checked September 22, 2026